NEXMED TO PRESENT AT THE ROTH 22nd ANNUAL OC GROWTH STOCK CONFERENCE

• SAN DIEGO-- (BUSINESS WIRE)-- NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of products based on the NexACT^® technology, announced today that Bassam Damaj, Ph.D., President and Chief Executive Officer, will present an overview of the Company at 1:00 p.m. Pacific Time on Wednesday, March 17, 2010 at the Roth 22nd Annual OC Growth Stock Conference.

  Interested parties may access the live webcast at the following URL http://www.wsw.com/webcast/roth23/nexm/.

  NexMed intends to file its Form 10K for the year ended December 31, 2009, on or before March 31, 2010. In addition, the Company's Annual Report for 2008 is available electronically on the Company's website: www.nexmed.com, or requests for hardcopies of the Annual Report can be made by contacting Ed Cox, at [email protected], 858-926-5811. Copies of the Annual Report will be provided upon request without charge.

  About NexMed, Inc.

  NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company's goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT^® drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer.

  NexMed Contacts:

  ---

  NexMed Investor Relations:
  Paula Schwartz
  
  NexMed, Inc. Rx Communications Group, LLC
  (917) 322-2216
  [email protected]
  
  Edward Cox, V.P.
  Investor Relations & Corporate Development NexMed, Inc.
  (858) 926-5811
  [email protected]